Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001549595-24-000139
Filing Date
2024-10-16
Accepted
2024-10-16 16:47:12
Documents
3
Period of Report
2024-10-15

Document Format Files

Seq Description Document Type Size
1 FORM 3 wk-form3_1729111624.html 3  
1 FORM 3 wk-form3_1729111624.xml 3 1655
2 EX-24 powerofattorneykapurconf.htm EX-24 4365
3 GRAPHIC powerofattorneykapurconf001.jpg GRAPHIC 226235
  Complete submission text file 0001549595-24-000139.txt   319258
Mailing Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158
Business Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158 (415) 660-5320
Nurix Therapeutics, Inc. (Issuer) CIK: 0001549595 (see all company filings)

EIN.: 270838048 | State of Incorp.: DE | Fiscal Year End: 1130
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 275 MADISON AVE SUITE 702 NEW YORK NY 10016
Business Address
Kapur Anil (Reporting) CIK: 0001730703 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-39398 | Film No.: 241375114